Skip to main content
. 2021 Dec 13;45(2):zsab291. doi: 10.1093/sleep/zsab291

Table 4.

Adjusted associations a between rest-activity characteristics and markers of glucose metabolism and insulin resistance in adults who did not take medications to lower blood sugar in NHANES 2011–2014.

Adjusted geometric mean (95% CI) b
Fasting glucose (mg/dL) Fasting insulin (uU/mL) HOMA-IR OGTT (mg/dL)
N 2794 2697 2697 2602
F statistic
 Q1 100.68 (97.68, 103.76) 10.95 (9.49, 12.62) 2.71 (2.31, 3.19) 118.59 (111.13, 126.57)
 Q2 101.16 (98.42, 103.98) 11.10 (9.98, 12.34) 2.77 (2.46, 3.12) 110.95 (105.03, 117.21)
 Q3 100.09 (97.25, 103.01) 10.12 (9.19, 11.14) 2.50 (2.22, 2.81) 109.11 (102.98, 115.63)
 Q4 99.30 (96.66, 102.00) 9.57 (8.58, 10.68) 2.35 (2.07, 2.65) 109.13 (101.95, 116.8)
 Q5 (ref) 98.04 (95.77, 100.38) 8.61 (7.67, 9.66) 2.09 (1.83, 2.39) 103.49 (97.58, 109.76)
p-trend .03 .0002 .0003 <.0001
Amplitude
 Q1 101.40 (98.59, 104.30) 11.13 (9.87, 12.68) 2.79 (2.43, 3.21) 117.92 (111.05, 123.97)
 Q2 102.54 (99.55, 105.61) 11.59 (10.49, 12.94) 2.95 (2.61, 3.34) 116.75 (112.17, 122.73)
 Q3 98.50 (96.17, 100.89) 9.39 (8.41, 10.49) 2.28 (2.02, 2.58) 108.85 (102.51, 116.75)
 Q4 97.86 (95.59, 100.16) 9.30 (8.33, 10.49) 2.26 (2.00, 2.57) 105.64 (99.48, 111.05)
 Q5 (ref) 99.30 (96.69, 101.98) 8.94 (7.92, 10.07) 2.19 (1.91, 2.50) 102.51 (96.54, 107.77)
p-trend .002 <.0001 <.0001 <.0001
Mesor
 Q1 101.49 (98.49, 105.64) 11.52 (10.23, 12.96) 2.89 (2.52, 3.31) 117.92 (111.05, 125.21)
 Q2 99.48 (97.51, 101.49) 10.61 (9.39, 11.99) 2.61 (2.28, 2.98) 108.85 (102.51, 115.58)
 Q3 99.48 (96.54, 101.49) 9.69 (8.60, 10.92) 2.38 (2.08, 2.72) 106.70 (100.48, 112.17)
 Q4 99.48 (96.54, 101.49) 8.90 (7.97, 9.95) 2.19 (1.92, 2.49) 109.95 (104.58, 115.58)
 Q5 (ref) 98.49 (95.58, 101.49) 9.04 (7.83, 10.45) 2.21 (1.88, 2.60) 105.64 (97.51, 113.30)
p-trend .18 <.0001 <.0001 0.003
Amplitude:mesor
 Q1 101.49 (98.49, 104.58) 10.59 (9.30, 12.06) 2.66 (2.29, 3.10) 115.32 (108.14, 122.97)
 Q2 100.48 (98.49, 103.54) 10.18 (8.94, 11.47) 2.51 (2.20, 2.89) 113.22 (106.74, 120.09)
 Q3 98.49 (95.58, 101.49) 10.18 (9.21, 11.36) 2.48 (2.20, 2.83) 108.40 (101.74, 115.49)
 Q4 98.49 (96.54, 101.49) 9.30 (8.33, 10.38) 2.27 (1.99, 2.59) 109.46 (103.71, 115.54)
 Q5 (ref) 99.48 (96.54, 102.51) 9.58 (8.50, 10.80) 2.34 (2.05, 2.66) 103.48 (97.02, 110.38)
p-trend .04 .02 .01 <.0001
Acrophase
 Q1 (ref) 98.52 (95.78, 101.33) 9.04 (8.61, 9.49) 2.25 (1.97, 2.58) 110.12 (103.76, 116.87)
 Q2 99.70 (97.30, 102.17) 9.60 (8.86, 10.41) 2.35 (2.06, 2.69) 107.25 (101.67, 113.15)
 Q3 100.31 (97.46, 103.24) 10.21 (9.55, 10.93) 2.52 (2.19, 2.90) 111.87 (105.49, 118.64)
 Q4 99.65 (97.41, 101.95) 10.28 (9.89, 10.69) 2.46 (2.18, 2.77) 107.57 (101.36, 114.16)
 Q5 100.34 (97.40, 103.38) 10.51 (10.02, 11.04) 2.65 (2.32, 3.04) 109.77 (103.11, 116.86)
p-trend .12 .0002 .001 .94

a Models are adjusted for age, gender, race/ethnicity, education, household income, marital status, smoking, alcohol consumption, BMI, and total energy intake.

b Raw marker levels were log-transformed and adjusted least squares means were back-transformed.

Abbreviations: BMI, body mass index; CI, confidence interval; HOMA-IR, homeostatic model assessment of insulin resistance; NHANES, National Health and Nutrition Examination Survey; OGTT, oral glucose tolerance test.